Maestros Electronics & Telecommunications Systems Ltd H1 FY26 – When Telemedicine Met “Tech Jugaad” and Started Printing Orders Like ECG Reports
1. At a Glance
If you thought stethoscopes were the ultimate medical tech, wait till you see Maestros Electronics & Telecommunications Systems Ltd (METS) — the smallcap wizard that builds ECG machines, telemedicine systems, and financial inclusion tech with more passion than budget. With a market cap of ₹67.8 crore, a current price of ₹123, and a P/E ratio of 18, this Tarapur-based multi-gadget innovator is juggling cardiology, fintech, and government automation — all under one humble balance sheet.
The company’s Q2 FY26 (September 2025) results clocked quarterly sales of ₹5.89 crore and a PAT of ₹0.65 crore, though that’s a sharp QoQ decline of 35.6%. But hey, in the land of smallcaps, one good ECG order from ESIC can bring back the heartbeat. With ROCE at 16.7%, ROE at 13.4%, and debt-to-equity at just 0.08, METS is practically debt-free — and emotionally attached to innovation.
While the stock has fallen ~27.8% over the last year, promoters have quietly raised their stake to 60.2%, proving they still believe in their machines (and maybe a divine comeback).
So, what happens when a homegrown tech player mixes medical devices, telemedicine dreams, and fintech chaos? Let’s plug in the monitor and find out.
2. Introduction
Maestros Electronics isn’t your typical BSE microcap story. It’s a beautiful blend of “Make in India” meets “Doctor on Wi-Fi.” Born in 2010, the company began designing healthcare electronics long before your smartwatch started pretending to measure your oxygen levels.
Their universe is divided into two galaxies — Electronics & Instrumentation (E&I) and Telemedicine. The first makes all the heartbeat-friendly gadgets like ECG machines, defibrillators, and patient monitors. The second builds telemedicine systems that let doctors sit comfortably in Mumbai while monitoring a patient coughing in Munger.
Now, the fun twist? They also make software and kiosks for financial inclusion and banking automation, working with players like Cholamandalam, IDFC Bank, Mahindra Finance, and ICICI Bank. Imagine a company that can process your ECG and your EMI — all before lunch.
Yet, like most smallcaps, it’s not all rosy. The latest half-yearly performance shows a slowdown. But considering METS has bagged massive orders for cardiac and multipara monitors worth over ₹6.5 crore in FY25 and FY26, the ECG line might just start trending upward again.
Still, with an industry P/E of ~33.9, the stock’s own P/E of 18 screams “undervalued with side effects.” The company’s story is part startup hustle, part small-town miracle, and part fiscal thriller.
3. Business Model – WTF Do They Even Do?
Let’s decode the METS universe in plain language.
At its core, the company designs, develops, and manufactures medical electronics. Think of it as the Indian cousin of Philips — if Philips had to fight for every hospital tender on GeM.
Their business revolves around:
Telemedicine Solutions: Remote patient monitoring systems that connect doctors and patients through real-time video, data, and devices. Their flagship eICU solution allows doctors to monitor critical care patients remotely — perfect for a world that wants health at home.
Medical Equipment: This includes ECG machines, fetal monitors, pulse oximeters, defibrillators, and patient monitors. Basically, everything that beeps in an ICU, METS probably makes a smaller, smarter, cheaper version.
Financial Inclusion Products: Devices and software for banking kiosks, Aadhaar authentication, and microfinance operations. METS has worked with L&T Finance, AGS Transact, Fullerton, and Novopay — essentially automating India’s cash-to-card journey.
Their business model thrives on custom design + in-house manufacturing. They don’t just sell; they develop, deploy, and maintain. That gives them recurring revenue potential — especially in telemedicine.
The company’s segmental split says it all:
Telemedicine: ~88% of revenue
Electronics & Instrumentation: ~12%
So, while everyone calls themselves a “tech company,” METS actually builds hardware and healthcare — the rarest combination in India since punctual doctors.
4. Financials Overview
Let’s get to the money and numbers that define the heartbeat of this business.
Quarterly Results (₹ in crore):
Metric
Latest Qtr (Sep 2025)
YoY Qtr (Sep 2024)
Prev Qtr (Jun 2025)
YoY %
QoQ %
Revenue
5.89
7.33
10.43
-19.6%
-43.6%
EBITDA
0.40
1.01
1.76
-60.4%
-77.3%
PAT
0.65
1.01
1.52
-35.6%
-57.2%
EPS (₹)
1.18
1.83
2.76
-35.5%
-57.2%
Commentary: The quarter looks weaker, thanks to order timing and slower government dispatches. But remember, this is the same company that can bag a ₹6.5 crore cardiac monitor order and swing back to profits next quarter. Volatility is baked into the METS recipe — like masala in Mumbai
